Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butaselen plus radiotherapy for postoperative high-grade spinal cord glioma
ChiCTR2600116732Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BS1801 in spinal glioma (4 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Adverse events (AE), Serious adverse events (SAE) and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
BS1801
03
Conditions
spinal glioma
Beyond the preview
Go deeper on ChiCTR2600116732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116732.